StoxZenith Drugs Limited
NSE: ZENITHDRUG · Unclassified
Ask the data
Instant answers about Zenith Drugs Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Revenue | 131.6 | 133.3 | 171.2 |
| EBITDA | 16.9 | 13.6 | 12.2 |
| Operating margin | 12.9% | 10.2% | 7.1% |
| Interest | 3.0 | 3.7 | 5.6 |
| Depreciation | 1.3 | 3.0 | 6.0 |
| Profit before tax | 13.3 | 9.3 | 5.4 |
| Tax | 3.8 | 2.1 | 1.4 |
| Net profit | 9.5 | 7.2 | 3.9 |
| EPS ₹ | 5.56 | 4.18 | 2.30 |
| Operating cash flow | -12.5 | -5.5 | 8.9 |
| Capex | 5.3 | 32.3 | 13.8 |
| Dividend paid | 0.0 | 0.0 | 0.0 |
| Total assets | — | 161.5 | 187.5 |
| Equity | — | 69.4 | 74.9 |
Half-yearly performance
last 6 half years · ₹ crore| H1 FY24* | H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|---|
| Revenue | 69.4 | 62.2 | 67.7 | 65.6 | 78.2 | 93.0 |
| Operating profit | 11.1 | 5.8 | 6.8 | 6.8 | 6.2 | 6.0 |
| Operating margin | 16.0% | 9.4% | 10.0% | 10.4% | 7.9% | 6.4% |
| Other income | 0.1 | 2.0 | 0.9 | 1.7 | 1.9 | 3.2 |
| Interest | 1.5 | 1.5 | 1.2 | 2.5 | 2.5 | 3.1 |
| Depreciation | 0.6 | 0.7 | 0.7 | 2.3 | 3.0 | 3.0 |
| Profit before tax | 7.6 | 5.7 | 5.7 | 3.5 | 2.3 | 3.0 |
| Tax | 1.9 | 1.8 | 0.0 | 2.1 | 0.0 | 1.4 |
| Net profit | 5.7 | 3.8 | 5.7 | 1.4 | 2.3 | 1.6 |
| EPS ₹ | 1.00 | 4.56 | 3.33 | 0.84 | 1.36 | 0.94 |
| Revenue YoY | — | — | -2.5% | 5.5% | 15.6% | 41.7% |
| Profit YoY | — | — | 0.4% | -62.5% | -59.1% | 11.8% |
Returns & margins
trailing-twelve-month, per half year| H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|
| ROE | — | 14.1% | 10.3% | 5.3% | 5.3% |
| ROCE | — | 13.2% | 11.0% | 8.8% | 8.5% |
| Net margin | 7.2% | 7.4% | 5.4% | 2.6% | 2.3% |
| EBITDA margin | 12.9% | 9.7% | 10.2% | 9.0% | 7.1% |
| Debt / equity | — | 0.58 | 0.70 | 0.72 | 0.74 |
| Interest coverage | 5.43 | 5.09 | 3.50 | 2.18 | 1.96 |
| Asset turnover | — | 0.90 | 0.83 | 0.87 | 0.91 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '24 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|
| Share capital | 17.1 | 17.1 | 17.1 | 17.1 |
| Other equity / reserves | 50.8 | 52.2 | 54.6 | 57.8 |
| Total equity | 67.9 | 69.4 | 71.7 | 74.9 |
| Borrowings | 39.5 | 48.6 | 51.9 | 55.1 |
| Current liabilities | 59.8 | 79.3 | 80.5 | 92.5 |
| Non-current liabilities | 15.9 | 12.8 | 13.1 | 20.1 |
| Total assets | 143.6 | 161.5 | 165.2 | 187.5 |
| Property, plant & equipment | 11.1 | 40.1 | 38.9 | 37.1 |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventories | 29.5 | 39.6 | 38.5 | 42.4 |
| Receivables | 63.7 | 60.6 | 59.6 | 73.3 |
| Cash & equivalents | 1.0 | 0.3 | 0.5 | 0.3 |
Cash flow
annual · ₹ crore · line = free cash flow| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Cash from operations | -12.5 | -5.5 | 8.9 |
| Cash from investing | -9.4 | -31.4 | -13.7 |
| Cash from financing | 30.5 | 28.4 | 4.8 |
| Capex | 5.3 | 32.3 | 13.8 |
| Free cash flow | -17.8 | -37.8 | -4.9 |
| Dividends paid | 0.0 | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Zenith Drugs Limited | 66 | 38.70 | 16.8 | 0.89 | 5.3% |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Zenith Drugs Limited?
Zenith Drugs Limited (ZENITHDRUG) closed at ₹38.70 on NSE on 06 Nov 2026.
What is the market cap of Zenith Drugs Limited?
₹66 crore at the latest close.
What is the P/E ratio of Zenith Drugs Limited?
16.8, on trailing-twelve-month earnings from its filings.
How fast is Zenith Drugs Limited growing?
Zenith Drugs Limited: Latest-half-year revenue is up 41.7% year on year, profit up 11.8%.
How profitable is Zenith Drugs Limited?
On a trailing-twelve-month basis return on equity is 5.3%, return on capital employed 8.5%, operating margin 7.1%, net margin 2.3%.
How much debt does Zenith Drugs Limited have?
Zenith Drugs Limited is moderately geared: debt to equity is 0.74 with borrowings of ₹55 cr against cash of ₹0 cr (balance sheet of 2026-03-31). Operating profit covers interest 2.0 times.
Financials parsed from Zenith Drugs Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Half-yearly from H1 FY24, annual from FY24, balance sheet from Sep '24. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.